First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Autor: A. Vergnenegre, A. Alexandru, Hiroshi Sakai, Helena Linardou, Michael Schenker, Claudia Caserta, László Urbán, Judith Raimbourg, Jacobus A. Burgers, Arteid Memaj, Suresh S. Ramalingam, Matthew D. Hellmann, Randeep Sangha, Martin Reck, Julie R. Brahmer, Mariano Provencio, Ki Hyeong Lee, Sang-We Kim, Clarisse Audigier-Valette, Luis Paz-Ares, Yuichiro Ohe, Hossein Borghaei, Kenneth J. O'Byrne, L. Lupinacci, Phuong Tran, Jong Seok Lee, Makoto Nishio, Kynan Feeney, Masayuki Takeda, Enric Carcereny, Adam Pluzanski, F. E. Nathan, Carlos Gallardo, Judith Bushong, Keunchil Park, B. Zurawski, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Gregory A. Otterson

Publikováno v: Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

[Introduction] In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified desc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f7125153a7a538998a341b2f60e83e
http://hdl.handle.net/10261/305831

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

Autor: K J, O'Byrne, K H, Lee, S-W, Kim, K, Park, M, Nishio, H, Sakai, Y, Ohe, T, Fukuhara, J-H, Kang, H, Daga, C-J, Yu, K, Hotta, H, Tanaka, M, Takeda, T, Yokoyama, F E, Nathan, J-S, Lee

Publikováno v: ESMO Open. 7:100394

Nivolumab plus ipilimumab demonstrated clinically meaningful improvement in efficacy versus chemotherapy with a manageable safety profile in patients with advanced non-small cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) express

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820e86a16ecc16f031781b466fa63218
https://doi.org/10.1016/j.esmoop.2022.100394

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Autor: Ki Hyeong Lee, Fiona Taylor, Romain Corre, F. E. Nathan, John R. Penrod, Rachael Lawrance, Martin Reck, Makoto Nishio, Yong Yuan, Michael DeRosa, Judith Raimbourg, Samreen Ahmed, Krzysztof Lesniewski-Kmak, Randeep Sangha, Eduardo Richardet, Mariano Provencio, Julie R. Brahmer, Fabio Franke, Kynan Feeney, Michael Schenker, Prabhu Bhagavatheeswaran

Publikováno v: Biblos-e Archivo. Repositorio Institucional de la UAM
instname

Background: In the phase I I I CheckMate 227 s tudy, fi r s t - l ine nivolumab þ ipilimumab significantly prolonged progression-free survival (co-primary endpoint) versus chemotherapy in patients with advanced nonesmall-cell lung cancer (NSCLC) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cafa90a6b0e0fe0dd56ea8ed396707e
https://pubmed.ncbi.nlm.nih.gov/31195357

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Autor: Helena Linardou, Hossein Borghaei, Ki Hyeong Lee, Suresh S. Ramalingam, Adam Pluzanski, Kenneth J. O'Byrne, Julie R. Brahmer, B. Zurawski, F. E. Nathan, Mariano Provencio, Tudor Ciuleanu, Sang-We Kim, Michael Schenker, Martin Reck, Matthew D. Hellmann, Clarisse Audigier-Valette, Jong Seok Lee, Reyes Bernabe Caro, Luis Paz-Ares

Publikováno v: Journal of Clinical Oncology. 38:9500-9500

9500 Background: In the phase 3 CheckMate 227 Part 1 (NCT02477826; minimum follow-up, 29.3 mo), 1L NIVO + IPI significantly improved overall survival (OS) vs chemo in treatment-naive patients (pts) with aNSCLC and tumor PD-L1 expression ≥ 1% (prima

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a131a1f00c11fa600e37865315f2d28d
https://doi.org/10.1200/jco.2020.38.15_suppl.9500

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

Autor: Julie R. Brahmer, E. De La Mora Jimenez, A. Alexandru, Hiroshi Sakai, Sang We Kim, S.S. Ramalingam, Istvan Albert, Martin Reck, Hossein Borghaei, R. Bernabe Caro, Kenneth J. O'Byrne, Prabhu Bhagavatheeswaran, Solange Peters, A. Vergnenegre, William J. Geese, Luis Paz-Ares, Matthew D. Hellmann, L. Lupinacci, F. E. Nathan, B. Zurawski

Publikováno v: Annals of Oncology. 30:v913-v914

Background Part 1 of CheckMate 227 (NCT02477826), a phase III study in 1L NSCLC, has dual primary endpoints. The primary endpoint of progression-free survival (PFS) with NIVO + IPI vs chemo in patients (pts) with tumor mutational burden ≥ 10 mut/Mb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee7d58e0551be9f3197fc9376ecb475f
https://doi.org/10.1093/annonc/mdz394.075